New Immunotherapy Is First Bladder Cancer Drug Approved By FDA In 30 Years
San Francisco-based Genentech Inc.'s new drug, Tecentriq, is expected to treat patients metastatic bladder cancer. Meanwhile, new research identifying breast cancer genes could aid treatment plans.
The San Francisco Business Times:
Genentech Wins FDA Approval Of First New Bladder Cancer Drug In 30 Years
Just two months after scoring the promise of a quick regulatory review, Genentech Inc. won Food and Drug Administration approval Wednesday of a new type of cancer immunotherapy drug against advanced bladder cancer that has spread to other parts of the body. (Leuty, 5/19)
Identification Of Breast Cancer Genes Raises Hopes For More Personalized Treatment
Like snowflakes, cancers are unique. And that is what makes them so hard to defend against — different tumors will not always react the same to one type of treatment. (Starr, 5/18)